Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Shanghai Siponuoyin Biotechnology Co Ltd

Clinical trials sponsored by Shanghai Siponuoyin Biotechnology Co Ltd, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Gene therapy SPOT-03 enters human testing for duchenne muscular dystrophy Results expected Dec 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1

Gene therapy SPOT-03 enters human testing for duchenne muscular dystrophy

Disease control Recruiting now

This early-phase trial tests a gene therapy called SPOT-03 in 9 boys with Duchenne muscular dystrophy (DMD), aged 2 to 8. The main goal is to see if the treatment is safe and tolerable. Researchers will also check if it increases dystrophin protein levels in muscles, which could …

Early phase 1 • Sponsor: Shanghai Siponuoyin Biotechnology Co Ltd • Aim: Disease control

Last updated Jun 27, 2026 12:30 UTC